XX ISSHP World Congress 2016

• Processo: 16/05263-8
• Modalidade de apoio: Auxílio Organização - Reunião Científica
• Data de Início da vigência: 23 de outubro de 2016
• Data de Término da vigência: 26 de outubro de 2016
• Área do conhecimento: Ciências da Saúde - Medicina - Saúde Materno-infantil
• Pesquisador responsável: Nelson Sass
• Beneficiário: Nelson Sass
• Instituição Sede: Escola Paulista de Medicina (EPM). Universidade Federal de São Paulo (UNIFESP). Campus São Paulo. São Paulo , SP, Brasil
• Assunto(s): Obstetrícia Morte materna Eclâmpsia Pré-eclâmpsia Hipertensão Hipertensão induzida pela gravidez Eventos científicos e de divulgação Reuniões científicas
• Palavra(s)-Chave do Pesquisador: Eclâmpsia | hipertensão arterial | morte materna | Pré-eclâmpsia | Obstetrícia

Resumo

Welcome and announcements Nelson Sass. Chair: What's new in Pregnancy Hypertension? Mark Brown, Australia; The EmPOWER. Shuchita Mundle, India; Can we improve standard of care world-wide? Peter Von Dadelszen, UK; The pathogenesis of PE: animals to humans, Annemarie Hennessy, Australia; PE: Immune and inflammatory mechanisms, Christopher Redman, UK; Angiogenic Factors : from Diagnosis to Therapy, Ananth Karumanchi, USA; Free fetal hemoglobin: a new etiological factor, a predictive and diagnostic biomarker. Stefan Hansson, Sweden; Pathophysiology and prevention of PE: diagnosis and biomarkers targeting placental secretion of anti-angiogenic factors to treat PE. Stephen Tong, Australia;TRUFFLE: The next steps. Christoph Lees, UK; Clinical trials: STAMP; IMPROvED; PARROTT. Alternative therapies for chronic hypertension in pregnancy, Jenny Myers, UK; Can we predict PE? The obesity epidemic: life course approach. Mark Hanson, UK; Screening for PE: an inverted pyramid? Fabricio S. Costa, Australia; A pyramid, an inverted pyramid or a tunnel? Gordon Smith, UK; Management based on risk stratification - PREPARE - Brazilian Trial. James Roberts, USA; Management; PE as a fetal disease; Experimental models in PE. Oral antihypertensives: new alternatives? Thomas Easterling, USA; Hemodynamic in PE. Herbert Valensise, Italy; "Omics" in PE: beyond biomarkers. Louise Kenny, Ireland; Young Investigators presentations. Vascular Biology of PE: where are we now? Marilyn Cipolla, USA; Can we apply programs from developed countries to low and middle income? Charlotte Warren, Population Council's. USA; Maternal and Perinatal Outcomes: a Brazilian network experience, José G. Cecatti, Brazil; PE is a world-wide disorder. Millennium goals and Brazil. Long term health after PE: risks and opportunities, Anne C. Staff, Norway; Antihypertensive therapy: lessons from CHIPS trial, Laura Magee, UK; When is the optimum time to deliver? Ben Mol, Australia. (AU)